Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

Company Overview

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021. The company has secured orphan drug designations from the U.S. Food and Drug Administration for its lead programs and established partnerships to support manufacturing and supply chain needs. With an integrated model that combines in-house research, process development and clinical operations, Taysha aims to accelerate the transition of its candidates from preclinical studies into human trials.

Through collaborations with academic institutions, patient advocacy groups and regulatory agencies, Taysha serves both domestic and international patient populations facing devastating genetic disorders. Its clinical trials are conducted across multiple trial sites in North America and Europe, with a focus on leveraging real-world insights to optimize study design and endpoint selection.

Led by a management team with deep expertise in gene therapy, translational research and rare disease development, Taysha Gene Therapies is committed to building a broad platform capable of delivering potentially transformative treatments for central nervous system disorders. The company continues to expand its scientific and clinical capabilities to bring durable, one-time gene therapies to patients worldwide.

Key Stats

• Today's Range: $2.82 to $2.94
• 50-Day Range: $2.31 to $3.03
• 52-Week Range: $1.05 to $3.31
• Volume: 2.03 million shs
• Average Volume: 2.65 million shs
• Market Capitalization: $791.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.29
• Consensus Rating: Buy

Taysha Gene Therapies Stock Analysis - MarketRank™

Taysha Gene Therapies scored higher than 36% of companies evaluated by MarketBeat, and ranked 761st out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Taysha Gene Therapies has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Taysha Gene Therapies is -8.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Taysha Gene Therapies is -8.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Taysha Gene Therapies has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.35% of the outstanding shares of Taysha Gene Therapies have been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Taysha Gene Therapies has recently decreased by 4.71%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Taysha Gene Therapies does not currently pay a dividend.

Dividend Growth

Taysha Gene Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.35% of the outstanding shares of Taysha Gene Therapies have been sold short.

Short Interest Ratio / Days to Cover

Taysha Gene Therapies has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Taysha Gene Therapies has recently decreased by 4.71%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.28

News Sentiment

Taysha Gene Therapies has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.

Search Interest

Only 7 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.78% of the stock of Taysha Gene Therapies is held by insiders.

Percentage Held by Institutions

77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSHA Stock Analysis - Frequently Asked Questions

How have TSHA shares performed this year?

Taysha Gene Therapies' stock was trading at $1.73 at the beginning of the year. Since then, TSHA shares have increased by 67.6% and is now trading at $2.90.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.02. The firm had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.61 million. Taysha Gene Therapies had a negative trailing twelve-month return on equity of 78.44% and a negative net margin of 1,144.97%.
Read the conference call transcript.

When did Taysha Gene Therapies IPO?

Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

Who are Taysha Gene Therapies' major shareholders?

Top institutional shareholders of Taysha Gene Therapies include Octagon Capital Advisors LP (5.87%), Jefferies Financial Group Inc. (4.80%), Adage Capital Partners GP L.L.C. (2.25%) and Tybourne Capital Management HK Ltd. (1.91%). Insiders that own company stock include RA Session II, Paul B Manning, Sean P Nolan, Kamran Alam and Sukumar Nagendran.
View institutional ownership trends.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Taysha Gene Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Taysha Gene Therapies investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alphabet (GOOG), Visa (V) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSHA
• CIK: 1806310
• Web: www.tayshagtx.com
• Phone: 214-612-0000
• Fax: N/A
• Employees: 180
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Taysha Gene Therapies: $8.29
• High Price Target: $11.00
• Low Price Target: $6.00
• Potential Upside/Downside: +185.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$89.30 million
• Net Margins: -1,144.97%
• Pretax Margin: -1,144.97%
• Return on Equity: -78.44%
• Return on Assets: -44.82%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 12.48
• Quick Ratio: 12.48

Sales & Book Value

• Annual Sales: $8.33 million
• Price / Sales: 94.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.91 per share
• Price / Book: 3.19

Miscellaneous

• Outstanding Shares: 272,800,000
• Free Float: 262,483,000
• Market Cap: $791.12 million
• Optionable: Optionable
• Beta: 0.98